Logo image of FRX.CA

FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:FRX - CA31447P1009 - Common Stock

10.65 CAD
+0.24 (+2.31%)
Last: 1/7/2026, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FRX. FRX was compared to 22 industry peers in the Biotechnology industry. While FRX seems to be doing ok healthwise, there are quite some concerns on its profitability. FRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year FRX has reported negative net income.
FRX had a negative operating cash flow in the past year.
FRX had negative earnings in each of the past 5 years.
FRX had negative operating cash flow in 4 of the past 5 years.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

FRX has a better Return On Assets (-14.09%) than 77.27% of its industry peers.
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROIC N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

FRX has a better Gross Margin (93.12%) than 100.00% of its industry peers.
FRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

FRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FRX has more shares outstanding
Compared to 1 year ago, FRX has an improved debt to assets ratio.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

FRX has an Altman-Z score of -2.09. This is a bad value and indicates that FRX is not financially healthy and even has some risk of bankruptcy.
FRX has a better Altman-Z score (-2.09) than 63.64% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.09
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

FRX has a Current Ratio of 4.69. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
FRX has a better Current ratio (4.69) than 81.82% of its industry peers.
A Quick Ratio of 4.44 indicates that FRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.44, FRX belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.44
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for FRX have decreased strongly by -475.00% in the last year.
Looking at the last year, FRX shows a very negative growth in Revenue. The Revenue has decreased by -21.39% in the last year.
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%

3.2 Future

FRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 240523.00% yearly.
Based on estimates for the next years, FRX will show a very strong growth in Revenue. The Revenue will grow by 24.44% on average per year.
EPS Next Y-227846112347928100%
EPS Next 2Y10945453561.11%
EPS Next 3Y26670700%
EPS Next 5Y240523%
Revenue Next Year-20.4%
Revenue Next 2Y16.66%
Revenue Next 3Y17.6%
Revenue Next 5Y24.44%

3.3 Evolution

FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

FRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 11.60, the valuation of FRX can be described as very reasonable.
Based on the Price/Forward Earnings ratio, FRX is valued cheaper than 95.45% of the companies in the same industry.
FRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.57.
Industry RankSector Rank
PE N/A
Fwd PE 11.6
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as FRX's earnings are expected to grow with 26670700.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10945453561.11%
EPS Next 3Y26670700%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

FENNEC PHARMACEUTICALS INC

TSX:FRX (1/7/2026, 7:00:00 PM)

10.65

+0.24 (+2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners42.53%
Inst Owner ChangeN/A
Ins Owners1.85%
Ins Owner ChangeN/A
Market Cap363.70M
Revenue(TTM)38.79M
Net Income(TTM)-6.94M
Analysts85.45
Price Target19.53 (83.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-95.59%
Min EPS beat(2)-199.56%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)-67.7%
Min EPS beat(4)-199.56%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-157.9%
EPS beat(12)5
Avg EPS beat(12)-104.64%
EPS beat(16)6
Avg EPS beat(16)-92.56%
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-0.57%
Max Revenue beat(2)8.54%
Revenue beat(4)2
Avg Revenue beat(4)-10.17%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)8.54%
Revenue beat(8)4
Avg Revenue beat(8)-7.28%
Revenue beat(12)6
Avg Revenue beat(12)2.86%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.51%
EPS NQ rev (1m)37.5%
EPS NQ rev (3m)-63.58%
EPS NY rev (1m)17.33%
EPS NY rev (3m)-406.93%
Revenue NQ rev (1m)2.08%
Revenue NQ rev (3m)-7.18%
Revenue NY rev (1m)2.47%
Revenue NY rev (3m)-3.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.6
P/S 6.79
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)0.92
Fwd EY8.62%
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS1.57
BVpS-0.18
TBVpS-0.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.12%
FCFM N/A
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.44
Altman-Z -2.09
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-475%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.48%
EPS Next Y-227846112347928100%
EPS Next 2Y10945453561.11%
EPS Next 3Y26670700%
EPS Next 5Y240523%
Revenue 1Y (TTM)-21.39%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%78.69%
Revenue Next Year-20.4%
Revenue Next 2Y16.66%
Revenue Next 3Y17.6%
Revenue Next 5Y24.44%
EBIT growth 1Y-340.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year863.44%
EBIT Next 3Y338.18%
EBIT Next 5YN/A
FCF growth 1Y60.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.53%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FRX.CA FAQ

What is the ChartMill fundamental rating of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA.


What is the valuation status of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

ChartMill assigns a valuation rating of 3 / 10 to FENNEC PHARMACEUTICALS INC (FRX.CA). This can be considered as Overvalued.


What is the profitability of FRX stock?

FENNEC PHARMACEUTICALS INC (FRX.CA) has a profitability rating of 1 / 10.